Dr. Behzad Aghazadeh has served as Chairman of our Board of Directors since March 2017 and brings more than 20 years of experience in the biopharmaceutical industry, across various disciplines. The majority of Behzad’s career has been spent in healthcare investing, and he currently serves as Managing Partner and Portfolio Manager of Avoro Capital Advisors, LLC, an SEC registered investment manager. Behzad began his career in healthcare as a research scientist, later joining Booz Allen (now a unit of PricewaterhouseCoopers) as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries.
Dr. Aghazadeh holds a Masters in Physics from Ludwig-Maximilians University and a Ph.D. in Biochemistry & Biophysics from Cornell University.
Year Joined: 2017
Usama has over 25 years of experience in the technology, telecoms, and healthcare industries in key leadership roles ranging from corporate strategy, mergers and acquisitions, venture investing, product development, and operational management. He has worked on large-scale transformations across Fortune 500 companies, while helping to scale and grow numerous venture-backed and mid-sized organizations. He has lead key strategic efforts to bolster company balance sheets, take out costs, generate new revenue streams, raise capital, and lead multibillion dollar M&A transactions.
Usama holds a B.Sc, Electrical Engineering degree from University of Maryland at College Park and an M.B.A. Finance, Strategy, Entrepreneurship from INSEAD.
Year Joined: 2017
Brendan joined Immunomedics as Chief Commercial officer in November 2017. He has more than 22 years of global pharmaceutical and biotechnology experience, most recently serving as Vice President of U.S. Commercial Hematology-Oncology at Celgene Corporation. Brendan has led several successful product launches for blockbuster brands across both oncology and hematology. His deep commercial background and proven leadership will help drive Immunomedics to become a global oncology leader.
Brendan holds a B.S. Biological Sciences degree from Rutgers University and an M.B.A. Finance degree from The Stern School of Business at NYU.
Year Joined: 2017
Kurt has 25 years of human resources experience, principally in the Life Sciences and Biotechnology industries.
Kurt holds a B.A., in Liberal Arts and Sciences degree, and an M.A., in Labor and Industrial Relations degree both from University of Illinois at Urbana-Champaign
Year Joined: 2018
Jared oversees all aspects of Immunomedics’ Legal, Compliance and Intellectual Property functions. Jared brings more than 20 years of in-house executive legal experience in both the pharmaceuticals and pharma services industries, supporting the development and commercialization of a wide variety of products in numerous indication areas.
Jared holds a J.D degree from Duke University School of Law and a B.A degree from the University of Pennsylvania.
Year Joined: 2018
Bryan joined Immunomedics in February 2019 bringing more than 23 years of experience in Quality Operations, Systems, and Compliance in the Pharmaceutical, Biopharmaceutical and Medical Device industries. Prior to joining Immunomedics, Bryan was the Senior Vice President of Global Quality and EHS for Mallinckrodt Pharmaceuticals. Prior to Mallinckrodt, Bryan was the Vice President of Quality and Regulatory at Ben Venue Laboratories, a Boehringer-Ingelheim company.
Bryan holds a B.S. Biology degree from Central Michigan University, an M.S. Cellular and Molecular Biology degree from University of North Carolina at Charlotte, and an MBA, Finance degree from Westminster College.
Year Joined: 2019
Dr. Itri has decades of experience and a strong track record of bringing innovative drugs to market for multiple biopharma organizations. She was most recently the Executive Vice President of Global Health Sciences & Regulatory Affairs at The Medicines Company where she oversaw the development and regulatory approval of a variety of products. Previously, she was president of Pharmaceutical Development and CMO at Genta, Inc., involved in the development of therapeutic agents for breast cancer and chronic lymphocytic leukemia.
Prior to that, Dr. Itri served as Senior Vice President of Medical and Regulatory Affairs at Johnson & Johnson’s Pharmaceutical Research Institute, where she oversaw the development and approval of several products, including Procrit, Cladribine, and Tramadol. In addition, she served as Senior Vice President of Clinical Affairs and CMO for Ortho Biotech Inc. Dr. Itri began her career at Hoffmann-La Roche, as Assistant Vice President of Clinical Development in immunology and oncology.
Dr. Itri received her M.D. from New York Medical College, completed her medical residency at SUNY-Stony Brook and her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where she was an adjunct attending physician for more than 15 years. Dr. Itri has served as a member of the National Cancer Institute Board of Scientific Counselors and has published extensively on the development of therapeutic agents.
Year Joined: 2020